Prelude Therapeutics, Incorporated

Contributing Author

Recent Articles by Prelude Therapeutics, Incorporated

Feb-03	Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor PRLD +12.81% GlobeNewswire
Dec-06	Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs PRLD GlobeNewswire
Nov-12	Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update PRLD +8.89% GlobeNewswire
Nov-04	Prelude Therapeutics Announces Strategic Business Update PRLD -55.78% GlobeNewswire
Nov-04	Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors PRLD -55.78% GlobeNewswire
Nov-03	Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting PRLD +150.31% GlobeNewswire
Oct-17	Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors PRLD -9.16% GlobeNewswire
Aug-14	Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRLD GlobeNewswire
Jun-02	Prelude Therapeutics to Participate in Upcoming Healthcare Conferences PRLD GlobeNewswire
May-06	Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PRLD GlobeNewswire